Practical aspects of genetic counseling in breast cancer: Lights and shadows

Breast

Volumn 22, Issue 4, 2013, Pages 375-382

  Christinat, Alexandre ^a   Pagani, Olivia ^a,b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

BRCA1; BRCA2; Counseling; Hereditary breast cancer

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLAPARIB; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; RETINOID DERIVATIVE; TAMOXIFEN;

BRCA2 GENE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERM LINE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; MUTATIONAL ANALYSIS; OVARY CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; TUMOR SUPPRESSOR GENE;

EID: 84879781353     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.006     Document Type: Review

References (118)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 2000, 100(1):57-70.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
3. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378(6559):789-792.
4. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
5. Daly M.B., Axilbund J.E., Buys S., Crawford B., Farrell C.D., Friedman S., et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010, 8(5):562-594.
6. Fackenthal J.D., Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7(12):937-948.
7. Johannesdottir G., Gudmundsson J., Bergthorsson J.T., Arason A., Agnarsson B.A., Eiriksdottir G., et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996, 56(16):3663-3665.
8. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333. PMCID: 2267287.
9. van der Kolk D.M., de Bock G.H., Leegte B.K., Schaapveld M., Mourits M.J., de Vries J., et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010, 124(3):643-651.
10. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22studies. Am J Hum Genet. 2003, 72(5):1117-1130. PMCID: 1180265.
11. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62(3):676-689. PMCID: 1376944.
12. Metcalfe K., Lynch H.T., Ghadirian P., Tung N., Olivotto I., Warner E., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22(12):2328-2335.
13. Liede A., Karlan B.Y., Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004, 22(4):735-742.
14. Foulkes W.D. Inherited susceptibility to common cancers. N Engl J Med 2008, 359(20):2143-2153.
15. Agalliu I., Gern R., Leanza S., Burk R.D. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res. 2009, 15(3):1112-1120.
16. Kirchhoff T., Kauff N.D., Mitra N., Nafa K., Huang H., Palmer C., et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res. 2004, 10(9):2918-2921.
17. Gallagher D.J., Gaudet M.M., Pal P., Kirchhoff T., Balistreri L., Vora K., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010, 16(7):2115-2121.
18. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., Hoogerbrugge N., Verhoef S., Vasen H.F., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005, 42(9):711-719. PMCID: 1736136.
19. Armes J.E., Trute L., White D., Southey M.C., Hammet F., Tesoriero A., et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999, 59(8):2011-2017.
20. Atchley D.P., Albarracin C.T., Lopez A., Valero V., Amos C.I., Gonzalez-Angulo A.M., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26(26):4282-4288.
21. Gonzalez-Angulo A.M., Timms K.M., Liu S., Chen H., Litton J.K., Potter J., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011, 17(5):1082-1089. PMCID: 3048924.
22. Young S.R., Pilarski R.T., Donenberg T., Shapiro C., Hammond L.S., Miller J., et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009, 9:86. PMCID: 2666759.
23. Zhang L., Kirchhoff T., Yee C.J., Offit K. A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing. J Mol Diagn 2009, 11(3):176-181. PMCID: 2671333.
24. Mangold K.A., Wang V., Weissman S.M., Rubinstein W.S., Kaul K.L. Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences. J Mol Diagn 2010, 12(1):20-26. PMCID: 2797714.
25. Weischer M., Bojesen S.E., Ellervik C., Tybjaerg-Hansen A., Nordestgaard B.G. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008, 26(4):542-548.
26. Riley B.D., Culver J.O., Skrzynia C., Senter L.A., Peters J.A., Costalas J.W., et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012, 21(2):151-161.
27. Robson M.E., Storm C.D., Weitzel J., Wollins D.S., Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010, 28(5):893-901.
28. Trepanier A., Ahrens M., McKinnon W., Peters J., Stopfer J., Grumet S.C., et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 2004, 13(2):83-114.
29. Bennett R.L., French K.S., Resta R.G., Doyle D.L. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 2008, 17(5):424-433.
30. Qureshi N., Wilson B., Santaguida P., Carroll J., Allanson J., Culebro C.R., et al. Collection and use of cancer family history in primary care. Evid Rep Technol Assess (Full Rep) 2007, (159):1-84.
31. Calzone K.A., Soballe P.W. Genetic testing for cancer susceptibility. Surg Clin North Am. 2008, 88(4):705-721. v.
32. Balmana J., Diez O., Rubio I.T., Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011, 22(Suppl 6):vi31-vi34.
33. Frank T.S., Deffenbaugh A.M., Reid J.E., Hulick M., Ward B.E., Lingenfelter B., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20(6):1480-1490.
34. Pruthi S., Gostout B.S., Lindor N.M. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc. 2010, 85(12):1111-1120. PMCID: 2996153.
35. Lerman C., Shields A.E. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nat Rev Cancer 2004, 4(3):235-241.
36. Lerman C., Narod S., Schulman K., Hughes C., Gomez-Caminero A., Bonney G., et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275(24):1885-1892.
37. Vashlishan Murray A.B., Carson M.J., Morris C.A., Beckwith J. Illusions of scientific legitimacy: misrepresented science in the direct-to-consumer genetic-testing marketplace. Trends Genet. 2010, 26(11):459-461.
38. Jacobi C.E., de Bock G.H., Siegerink B., van Asperen C.J. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?. Breast Cancer Res Treat 2009, 115(2):381-390.
39. Kwon J.S., Gutierrez-Barrera A.M., Young D., Sun C.C., Daniels M.S., Lu K.H., et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010, 28(27):4214-4220.
40. Barcenas C.H., Hosain G.M., Arun B., Zong J., Zhou X., Chen J., et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 2006, 24(3):354-360.
41. Antoniou A.C., Pharoah P.P., Smith P., Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004, 91(8):1580-1590. PMCID: 2409934.
42. Berry D.A., Iversen E.S., Gudbjartsson D.F., Hiller E.H., Garber J.E., Peshkin B.N., et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002, 20(11):2701-2712.
43. Couch F.J., DeShano M.L., Blackwood M.A., Calzone K., Stopfer J., Campeau L., et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997, 336(20):1409-1415.
44. Shattuck-Eidens D., Oliphant A., McClure M., McBride C., Gupte J., Rubano T., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997, 278(15):1242-1250.
45. Tyrer J., Duffy S.W., Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004, 23(7):1111-1130.
46. James P.A., Doherty R., Harris M., Mukesh B.N., Milner A., Young M.A., et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006, 24(4):707-715.
47. Panchal S.M., Ennis M., Canon S., Bordeleau L.J. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet. 2008, 9:116. PMCID: 2630980.
48. Evans D.G., Eccles D.M., Rahman N., Young K., Bulman M., Amir E., et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004, 41(6):474-480. PMCID: 1735807.
49. Euhus D.M., Smith K.C., Robinson L., Stucky A., Olopade O.I., Cummings S., et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002, 94(11):844-851.
50. Marroni F., Aretini P., D'Andrea E., Caligo M.A., Cortesi L., Viel A., et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet. 2004, 41(4):278-285. PMCID: 1735736.
51. Schwartz M.D., Peshkin B.N., Hughes C., Main D., Isaacs C., Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002, 20(2):514-520.
52. Coyne J.C., Kruus L., Racioppo M., Calzone K.A., Armstrong K. What do ratings of cancer-specific distress mean among women at high risk of breast and ovarian cancer?. Am J Med Genet A 2003, 116A(3):222-228.
53. Hamilton J.G., Lobel M., Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009, 28(4):510-518. PMCID: 2807362.
54. Bosch N., Junyent N., Gadea N., Brunet J., Ramon Y.C.T., Torres A., et al. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?. Breast 2012, 21(6):755-760.
55. Chenevix-Trench G., Healey S., Lakhani S., Waring P., Cummings M., Brinkworth R., et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006, 66(4):2019-2027.
56. Warner E., Plewes D.B., Hill K.A., Causer P.A., Zubovits J.T., Jong R.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317-1325.
57. Komenaka I.K., Ditkoff B.A., Joseph K.A., Russo D., Gorroochurn P., Ward M., et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004, 100(10):2079-2083.
58. Scheuer L., Kauff N., Robson M., Kelly B., Barakat R., Satagopan J., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002, 20(5):1260-1268.
59. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
60. NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2012. National Comprehensive Cancer Network Guidelines 2012.
61. Kriege M., Brekelmans C.T., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437.
62. Stoutjesdijk M.J., Boetes C., Jager G.J., Beex L., Bult P., Hendriks J.H., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001, 93(14):1095-1102.
63. Ziv E., Shepherd J., Smith-Bindman R., Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003, 95(7):556-558.
64. Warner E., Messersmith H., Causer P., Eisen A., Shumak R., Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008, 148(9):671-679.
65. Le-Petross H.T., Whitman G.J., Atchley D.P., Yuan Y., Gutierrez-Barrera A., Hortobagyi G.N., et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011, 117(17):3900-3907.
66. Grann V.R., Jacobson J.S., Thomason D., Hershman D., Heitjan D.F., Neugut A.I. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 2002, 20(10):2520-2529.
67. Kurian A.W., Sigal B.M., Plevritis S.K. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010, 28(2):222-231. PMCID: 2815712.
68. Plevritis S.K., Kurian A.W., Sigal B.M., Daniel B.L., Ikeda D.M., Stockdale F.E., et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006, 295(20):2374-2384.
69. Pijpe A., Andrieu N., Easton D.F., Kesminiene A., Cardis E., Nogues C., et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012, 345:e5660.
70. Narod S.A., Lubinski J., Ghadirian P., Lynch H.T., Moller P., Foulkes W.D., et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006, 7(5):402-406.
71. Evans D.G., Gaarenstroom K.N., Stirling D., Shenton A., Maehle L., Dorum A., et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009, 46(9):593-597.
72. Woodward E.R., Sleightholme H.V., Considine A.M., Williamson S., McHugo J.M., Cruger D.G. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007, 114(12):1500-1509.
73. Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340(2):77-84.
74. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93(21):1633-1637.
75. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van 't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22(6):1055-1062.
76. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304(9):967-975. PMCID: 2948529.
77. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345(3):159-164.
78. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101(2):80-87. PMCID: 2639318.
79. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346(21):1616-1622.
80. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346(21):1609-1615.
81. Eisen A., Lubinski J., Klijn J., Moller P., Lynch H.T., Offit K., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23(30):7491-7496.
82. Kauff N.D., Domchek S.M., Friebel T.M., Robson M.E., Lee J., Garber J.E., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008, 26(8):1331-1337. PMCID: 3306809.
83. King M.C., Wieand S., Hale K., Lee M., Walsh T., Owens K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286(18):2251-2256.
84. Gronwald J., Tung N., Foulkes W.D., Offit K., Gershoni R., Daly M., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118(9):2281-2284.
85. Peshkin B.N., Isaacs C., Finch C., Kent S., Schwartz M.D. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003, 21(23):4322-4328.
86. Goss P.E., Ingle J.N., Ales-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364(25):2381-2391.
87. Cuzick J., DeCensi A., Arun B., Brown P.H., Castiglione M., Dunn B., et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011, 12(5):496-503.
88. Iodice S., Barile M., Rotmensz N., Feroce I., Bonanni B., Radice P., et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010, 46(12):2275-2284.
89. Nkondjock A., Robidoux A., Paredes Y., Narod S.A., Ghadirian P. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 2006, 98(3):285-294.
90. Nkondjock A., Ghadirian P. Diet quality and BRCA-associated breast cancer risk. Breast Cancer Res Treat 2007, 103(3):361-369.
91. Trainer A.H., Lewis C.R., Tucker K., Meiser B., Friedlander M., Ward R.L. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010, 7(12):708-717.
92. Schwartz M.D., Lerman C., Brogan B., Peshkin B.N., Halbert C.H., DeMarco T., et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22(10):1823-1829.
93. Boughey J.C., Hoskin T.L., Degnim A.C., Sellers T.A., Johnson J.L., Kasner M.J., et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010, 17(10):2702-2709.
94. Bedrosian I., Hu C.Y., Chang G.J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010, 102(6):401-409.
95. Lostumbo L., Carbine N.E., Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010, (11). CD002748.
96. Morrow M., Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction. Br J Surg 2009, 96(1):1-2.
97. Haffty B.G., Harrold E., Khan A.J., Pathare P., Smith T.E., Turner B.C., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359(9316):1471-1477.
98. Pierce L.J., Levin A.M., Rebbeck T.R., Ben-David M.A., Friedman E., Solin L.J., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006, 24(16):2437-2443.
99. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., Bruggenwirth H.T., Tilanus-Linthorst M.M., Bartels C.C., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006, 17(3):391-400.
100. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002, 21(58):8981-8993.
101. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
102. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
103. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12(9):852-861.
104. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008, 108(2):289-296.
105. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28(3):375-379.
106. Lee E.H., Park S.K., Park B., Kim S.W., Lee M.H., Ahn S.H., et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat 2010, 122(1):11-25.
107. Murphy R.X., Adkinson J.M., Namey T., Eid S., Bleznak A. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy. Ann Plast Surg 2010, 64(5):684-687.
108. Anderson K., Jacobson J.S., Heitjan D.F., Zivin J.G., Hershman D., Neugut A.I., et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006, 144(6):397-406.
109. Quillin J.M., Lyckholm L.J. A principle-based approach to ethical issues in predictive genetic testing for breast cancer. Breast Dis 2006, 27:137-148.
110. Surbone A. Social and ethical implications of BRCA testing. Ann Oncol 2011, 22(Suppl 1):i60-i66.
111. Lodder L., Frets P.G., Trijsburg R.W., Tibben A., Meijers-Heijboer E.J., Duivenvoorden H.J., et al. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet. 2001, 9(7):492-500.
112. Hallowell N., Arden-Jones A., Eeles R., Foster C., Lucassen A., Moynihan C., et al. Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociol Health Illn 2006, 28(7):969-988.
113. Kinney A.Y., Bloor L.E., Mandal D., Simonsen S.E., Baty B.J., Holubkov R., et al. The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. Cancer 2005, 104(11):2508-2516.
114. Andrews L., Meiser B., Apicella C., Tucker K. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. Genet Test 2004, 8(3):240-247.
115. Claes E., Evers-Kiebooms G., Boogaerts A., Decruyenaere M., Denayer L., Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 2003, 116A(1):11-19.
116. Douglas H.A., Hamilton R.J., Grubs R.E. The effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews. J Genet Couns 2009, 18(5):418-435.
117. Bradbury A.R., Patrick-Miller L., Egleston B.L., Olopade O.I., Daly M.B., Moore C.W., et al. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer 2012, 118(13):3417-3425. PMCID: 3326182.
118. Sherman K.A., Kasparian N.A., Mireskandari S. Psychological adjustment among male partners in response to women's breast/ovarian cancer risk: a theoretical review of the literature. Psychooncology 2010, 19(1):1-11.